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Coronary Flow Reserve During Dipyridamole
Stress Echocardiography Predicts Mortality
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Lucca, Mestre-Venice, and Pisa, Italy
O B J E C T I V E S The goal of this study was to evaluate the ability of coronary ﬂow reserve (CFR) over
regional wall motion to predict mortality in patients with known or suspected coronary artery disease
(CAD).
B A C KG ROUND CFR evaluated using pulsed Doppler echocardiography testing on left anterior
descending artery is the state-of-the-art method during vasodilatory stress echocardiography.
METHOD S In a prospective, multicenter, observational study, we evaluated 4,313 patients (2,532
men; mean age 65  11 years) with known (n  1,547) or suspected (n  2,766) CAD who underwent
high-dose dipyridamole (0.84 mg/kg over 6 min) stress echocardiography with CFR evaluation of left
coronary descending artery (LAD) by Doppler. Overall mortality was the only endpoint analyzed.
R E S U L T S Stress echocardiography was positive for ischemia in 765 (18%) patients. Mean CFR was
2.35  0.68. At individual patient analysis, 1,419 (33%) individuals had CFR 2. During a median
follow-up of 19 months (1st quartile 8; 3rd quartile 36), 146 patients died. The 4-year mortality was
markedly higher in subjects with CFR 2 than in those with CFR 2, both considering the group with
ischemia (39% vs. 7%; p  0.0001) and the group without ischemia at stress echocardiography (12% vs.
3%; p  0.0001). At multivariable analysis, CFR on LAD 2 (hazard ratio [HR]: 3.31; 95% conﬁdence
interval [CI]: 2.29 to 4.78; p 0.0001), ischemia at stress echocardiography (HR: 2.40, 95% CI: 1.65 to 3.48,
p  0.0001), left bundle branch block (HR: 2.26, 95% CI: 1.50 to 3.41; p  0.0001), age (HR: 1.08, 95% CI:
1.06 –1.10; p 0.0001), resting wall motion score index (HR: 3.52, 95% CI: 2.38 to 5.21; p 0.0001), male
sex (HR: 1.74, 95% CI: 1.12 to 2.52; p  0.003), and diabetes mellitus (HR: 1.47, 95% CI: 1.03 to 2.08; p 
0.03) were independent predictors of mortality.
CONC L U S I O N S CFR on LAD is a strong and independent indicator of mortality, conferring
additional prognostic value over wall motion analysis in patients with known or suspected CAD. A
negative result on stress echocardiography with a normal CFR confers an annual risk of death 1% in
both patient groups. (J Am Coll Cardiol Img 2012;5:1079 – 85) © 2012 by the American College of
Cardiology Foundation
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he combination of conventional wall mo-
tion analysis with 2-dimensional echocardiog-
raphy and coronary flow reserve (CFR) with
pulsed Doppler flowmetry of mid-distal left
nterior descending artery (LAD) is the recom-
ended technique during vasodilator stress echo-
ardiography (1). CFR has the proven ability to
xert a powerful and additive prognostic value in
everal subsets of patients in large-scale multicenter
tudies: those with known or suspected coronary
rtery disease (CAD) (2), diabetes mellitus (3),
See page 1086
normal or near-normal coronary arteries (4), and
hypertension (5). It is equally effective for risk
stratification both in men and women with chest
pain and in those with normal results of dipyridam-
ole stress echocardiography according to wall mo-
tion criteria (6). In addition, CFR is not modulated
by concomitant medical therapy (5), allowing an
excellent risk stratification even in the presence of
negative result by wall motion analysis on
medical therapy (7,8). However, all previ-
ous studies have analyzed composite end-
points whereas mortality is the most clin-
ically meaningful prognostic endpoint
(9,10). It has already been demonstrated
that in patients with known or suspected
CAD pharmacological or exercise stress
echocardiography is an independent pre-
dictor of death, incremental to other clinical and
echocardiography parameters (11–13). The purpose
of this study was to assess the long-term value of
dipyridamole stress echocardiography with the
combined assessment of CFR on LAD for predict-
ing mortality in patients with known or suspected
CAD in a large-scale, multicenter, observational
and prospective study.
M E T H O D S
Patients. The initial population was represented by
,416 patients evaluated at 4 Italian Cardiology
nstitutions (Lucca, Mestre, Cesena, and Pisa) from
ugust 2003 to June 2011 for enrollment in a study
ocused on assessing the prognostic value of CFR in
he setting of known or suspected CAD. The study
esign was observational, not randomized, and
rospective; patient data were entered into the
atabank at the time of initial assessment. All
atients underwent stress echocardiography with
seall motion and CFR assessment of LAD by usingransthoracic Doppler ultrasound. Of the 4,416
atients initially selected, 103 (2%) were lost to
ollow-up. Thus, 4,313 (2,532 men; mean  SD
ge 65  11 years) formed the study group. Indi-
ations for stress echocardiography were suspected
AD in 2,766 (64%) subjects and risk stratification
f known CAD (i.e., history of myocardial infarc-
ion, coronary revascularization, and/or angio-
raphic evidence of 50% diameter coronary ste-
osis) in the remaining 1,547 (36%). According to
ndividual needs and physician’s choices, 2,515
58%) patients were evaluated after anti-ischemic
rugs had been discontinued, and 1,798 (42%)
atients were evaluated during anti-ischemic treat-
ent (Table 1). All patients gave their written
Table 1. Clinical and Echocardiographic Characteristics for




(n  1,419) p Value
Age, yrs 64 11 68 10 0.0001
Male 1,615 (56) 917 (65) 0.0001
Clinical history
Family history of CAD 743 (26) 365 (26) 0.97
Diabetes mellitus 550 (19) 429 (30) 0.0001
Arterial hypertension 1,865 (64) 1,026 (72) 0.0001
Hypercholesterolemia 1,519 (52) 845 (60) 0.0001
Smoking habit 867 (30) 444 (31) 0.37
Left bundle branch
block
177 (6) 133 (9) 0.0001
Prior myocardial
infarction
665 (23) 449 (32) 0.0001
Prior CABG 166 (6) 104 (7) 0.04
Prior PCI 626 (22) 364 (26) 0.003
Known CAD 949 (33) 598 (42) 0.0001
Anti-ischemic therapy at
the time of test
Beta-blockers 775 (27) 578 (41) 0.0001
Calcium antagonists 423 (15) 332 (23) 0.0001
Nitrates 229 (8) 236 (17) 0.0001
At least 1 medication 1,038 (36) 760 (54) 0.0001
Resting echocardiogram
WMA at rest 724 (25) 655 (46) 0.0001
WMSI at rest 1.10 0.24 1.26 0.37 0.0001
Left ventricular ejection
fraction %
57 7 53 10 0.0001
Stress echocardiography
Ischemic result 249 (9) 516 (36) 0.0001
WMSI at peak stress 1.11 0.30 1.34 0.39 0.0001
Resting velocity on
LAD, cm/s
31 9 40 22 0.0001
CFR on LAD 2.68 0.58 1.69 0.25 0.0001
Values are mean  SD or n (%).
CABG  coronary artery bypass graft; CAD  coronary artery disease; CFR 
coronary ﬂow reserve; LAD  left anterior descending artery; PCI  percuta-
neous coronary intervention; WMA  wall motion abnormality; WMSI  wallA B B R E V I A T I O N S
A N D A C R O N Y M S
CAD coronary artery disea
CFR coronary flow reserve
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1081informed consent before they underwent stress
echocardiography. When patients signed the writ-
ten informed consent form, they also authorized
physicians to use their clinical data. Stress echo-
cardiography data were collected and analyzed by
stress echocardiographers not involved in patient
care.
Stress echocardiography. Transthoracic stress echo-
ardiographic studies were performed with com-
ercially available ultrasound machines (Sonos
500 or iE 33, Philips Ultrasound, Andover, Mas-
achusetts; Vivid System 7, GE/Vingmed, Milwau-
ee, Wisconsin; Sequoia C256 Acuson Siemens
ountain View, California) equipped with multi-
requency, phased-array sector scan probe (S3–S8
r V3–V7) and with second harmonic technology.
wo-dimensional echocardiography and 12-lead
lectrocardiographic monitoring were performed in
ombination with high-dose dipyridamole admin-
stration (up to 0.84 mg over 6 min) (1). Echocar-
iographic images were semiquantitatively assessed
sing a 17-segment, 4-point scale model of the left
entricle (14). A wall motion score index was
erived by dividing the sum of individual segment
cores by the number of interpretable segments.
schemia was defined as stress-induced new and/or
orsening of pre-existing wall motion abnormality.
est wall motion abnormality was akinetic or dys-
inetic myocardium with no thickening during
tress. CFR was assessed during the standard stress
chocardiography examination by an intermittent
maging of both wall motion and LAD flow (1).
oronary flow in the mid-distal portion of LAD
as searched in the low parasternal long-axis sec-
ion under the guidance of color Doppler flow
apping (1). All studies were digitally stored to
implify off-line reviewing and measurements. Cor-
nary flow parameters were analyzed off-line using
he built-in calculation package of the ultrasound
nit. Flow velocities were measured 2 times for
ach study; namely, at baseline and at peak stress
before aminophylline injection). At each time
oint, 3 optimal profiles of peak diastolic Doppler
ow velocities were measured, and the results were
veraged. CFR was defined as the ratio between
yperemic peak and basal peak diastolic coronary
ow velocities. A CFR value 2.0 was considered
bnormal (3). All investigators of contributing cen-
ers passed quality control criteria for regional wall
otion and Doppler interpretation before entering
he study as previously described (15). The previ-
usly assessed intraobserver and interobserver vari-
bility for measurements of Doppler recordings and oegional wall motion analysis assessment were
10% (16).
Follow-up data. Follow-up data were obtained from
eview of the patient’s hospital record, personal
ommunication with the patient’s physician and
eview of the patient’s chart, a telephone interview
ith the patient or a patient’s close relative con-
ucted by trained personnel, or a staff physician
isiting the patients at regular intervals in the
utpatient clinic. Mortality was the only endpoint.
o avoid misclassification of the cause of death (9),
verall mortality was considered. Coronary revascu-
arization (surgery or angioplasty) was also regis-
ered; however, it was not identified as a clinical
vent, and patients were censored.
Statistical analysis. Continuous variables are ex-
pressed as mean  SD. Differences between groups
were compared using the Student t test and the
chi-square test, as appropriate. Mortality rates were
estimated with Kaplan-Meier curves and compared
using the log-rank test. Patients undergoing coro-
nary revascularization were censored at the time of
the procedure. Annual mortality was obtained from
Kaplan-Meier estimates to take censoring of the
data into account. The association of selected vari-
ables with outcome were assessed with the Cox
proportional hazards model using univariate and
stepwise multivariate procedures. In the Cox model,
the time-dependent revascularization effect was es-
timated. A significance of 0.05 was required for a
variable to be included in the multivariate model,
and 0.1 was the cutoff value for exclusion. Hazard
ratios (HRs) with the corresponding 95% confi-
dence intervals (CIs) were estimated. The following
covariates were analyzed: age, sex, left bundle
branch block, family history of CAD, diabetes
mellitus, arterial hypertension, hypercholesterol-
emia, smoking habit, previous myocardial infarc-
tion, previous coronary artery bypass graft, previous
percutaneous revascularization, ongoing anti-
ischemic therapy, resting wall motion abnormality,
resting wall motion score index, ischemia at stress
echocardiography, wall motion score index at peak
stress, test positivity, and CFR on LAD.
Statistical significance was set at p  0.05. SPSS
version 20 (SPSS Inc., Chicago, Illinois) was used
for analysis.
R E S U L T S
Stress echocardiographic ﬁndings. No complication
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10822.35  0.68. At individual patient analysis, 1,419
(33%) subjects had CFR 2 and 2,894 (67%) had
CFR 2. Stress echocardiography was positive for
ischemia in 765 (18%) individuals. Ischemia was
assessed in 516 patients with CFR 2 and in 249
patients with CFR 2 (36% vs. 9%; p  0.0001)
(Table 1).
Patients with CFR2 were older, more frequently
men, and had a higher incidence of diabetes mellitus,
arterial hypertension, hypercholesterolemia, left bun-
dle branch block, previous myocardial infarction, and
coronary revascularization (Table 1); in addition, they
were more frequently tested under anti-ischemic med-
ication than patients with CFR 2.
Survival analysis. During a median follow-up of 19
onths (interquartile range: 8 to 36 months), 146
3.4%) patients died.
According to the physician’s judgment, 907
21%) underwent myocardial revascularization (205
urgery and 702 percutaneous intervention) after a
edian of 111 days (1st quartile 30 days; 3rd
uartile 250 days) from the index stress echocar-
iography. There were 470 revascularizations in
atients with ischemia and 437 in those without
schemia at stress echocardiography (61% vs. 12%;
 0.0001). In addition, there were 635 revascu-
arizations in patients with CFR 2 and 272
evascularizations in those with CFR 2 (45% vs.
%; p  0.0001).
The 4-year mortality was significantly higher
n patients with CFR 2 than in patients with
FR 2, both considering the group with isch-
516 120 53 24 10
249 108 69 42 23
903 513 316 209 125
2,645 2,018 1,292 799 405
Follow-up (years)
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1
, CFR, and Risk
separated on the basis of presence () or absence () of ischemia
phy (SE) and coronary ﬂow reserve (CFR) on left anterior
or 2. Assuming a hazard ratio of 1 for the lowest mortality rate
hazard ratio with relative 95% conﬁdence intervals are reported in
er of patients per year is shown.mia (39% vs. 7%; p  0.0001) and the group
ithout ischemia at stress echocardiography (12%
s. 3%; p  0.0001) (Fig. 1). Interestingly, in
oth patient groups, CFR 2 was associated with
arkedly greater annual mortality in subjects
ith known CAD as well as in subjects with
uspected CAD (Fig. 2). Considering patients
ithout ischemia and CFR 2, annual mortality
as only 0.8% in those with known CAD and
.6% in those with suspected CAD. In the subset
f patients with suspected CAD and not under-
oing medical therapy at the time of testing, the
nnual mortality was 0.6% in those with CFR 2
nd 7.2% in those with CFR 2 (p  0.001).
Univariate indicators of mortality are listed in
able 2. At multivariable analysis, CFR on LAD
2 (HR: 3.31 [95% CI: 2.29 to 4.78]; p 
.0001), ischemia at stress echocardiography
HR: 2.40 [95% CI: 1.65 to 3.48]; p  0.0001),
left bundle branch block (HR: 2.26 [95% CI:
1.50 to 3.41]; p  0.0001), age (HR: 1.08 [95%
CI: 1.06 to 1.10]; p  0.0001), resting wall
motion score index (HR: 3.52 [95% CI: 2.38 to
5.21]; p  0.0001), male sex (HR: 1.74 [95% CI:
1.12 to 2.52]; p  0.003), and diabetes mellitus
(HR: 1.47 [95% CI: 1.03 to 2.08]; p  0.03) were
independent predictors of mortality. Revascular-
ization procedure did not exert any significant
effect (HR: 0.586 [95% CI: 0.80 to 4,284]) when
considered as a time-dependent covariate in the
Cox model.
D I S C U S S I O N
Dual-imaging vasodilator stress echocardiography
is an independent predictor of death in an unse-
lected cohort of patients, conferring useful prognos-
tic information in subjects with known CAD as
well as in those with suspected CAD. In particular,
test positivity by wall motion criteria with impaired
CFR on LAD identifies a particularly malignant
test response with a risk10% for annual mortality.
On the opposite side of the spectrum of risk
stratification, patients with no inducible ischemia
and normal CFR have an annual rate of death
1%. At intermediate risk are those patients who
have ischemia and preserved CFR and those who
have nonischemic test results and reduced CFR.
Comparison with previous studies. The value of
stress-induced wall motion abnormalities to predict
mortality has been extensively documented in pa-
tients with known or suspected CAD (11–13). OurSE + / CFR ≤ 2 
SE + / CFR >2 
SE - / CFR ≤ 2 
















subset (SE/CFR), thefindings confirm and expand those previous expe-
des
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1083riences, demonstrating an additive prognostic value
of CFR assessment on LAD over wall motion
analysis. In fact, a CFR 2 identified a subset of
patients at increased risk of mortality both in the
presence and in the absence of ischemia at stress
echocardiography.
The current study has major relevant differences
when compared with prior studies addressing the
issue of prediction of future events with stress
echocardiography. First, the study design is large-
scale and multicenter, which provides a realistic
picture of stress echocardiographic results obtained
































Figure 2. Annual Mortality Rate
Annual mortality in the group of patients with known coronary arte
ence () or absence () of ischemia at SE and CFR on left anterior





Family history of CAD 0.59 (0.37–0.93)
Diabetes mellitus 2.09 (1.48–2.95)
Arterial hypertension 1.35 (0.94–1.93)
Hypercholesterolemia 0.91 (0.66–1.26)
Smoking habit 1.09 (0.77–1.56)
Left bundle branch block 4.70 (3.24–6.83)
Prior myocardial infarction 1.60 (1.13–2.25)
Prior CABG 1.05 (0.55–2.00)
Prior PCI 1.02 (0.69–1.50)
Ongoing anti-ischemic therapy 1.65 (1.19–2.28)
WMSI at rest 8.41 (6.08–11.63)
Ischemia at stress echocardiography 5.56 (3.93–7.87)
Resting velocity on LAD 1.03 (1.02–1.04)
CFR on LAD 6.70 (4.74–9.47)CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in Table 1.tutions with on-site stress echocardiography inter-
pretation; this setting is able to evaluate the effec-
tiveness of pharmacological stress echocardiography
in prognosis. Second, the sample size consisted of
4,313 patients, which is the largest population
studied to date with combined CFR assessment,
large enough to provide prognostic information
only analyzing hard endpoints such as total mortal-
ity with no need to include surrogate or composite
endpoints (2–7) to increase the power of prognos-
tication. Third, the type of population analyzed
(i.e., low risk) was ideal to test the performance of















isease (CAD) and suspected CAD separated on the basis of pres-
cending artery 2 or 2. Abbreviations as in Figure 1.
nalysis Multivariate Analysis
p Value HR (95% CI) p Value
0.0001 1.08 (1.06–1.10) 0.0001
0.001 1.74 (1.21–2.52) 0.003
0.02









0.0001 3.52 (2.38–5.21) 0.0001
0.0001 2.40 (1.65–3.48) 0.0001
0.0001
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1084higher risk for mortality. Still, the high rate of
revascularizations, especially in the ischemic result
subset, may have lowered the power of stratification
of stress testing.
Clinical implications. There are several tests and
trategies for the evaluation of patients with
nown or suspected CAD, but no single strategy
as been demonstrated to be superior overall.
onetheless, the approach to these patients with
hysiological testing is sound, rational, and ef-
ective. Nowadays, the availability of high-tech
maging and its increasing and unrestricted use
17) is shadowing simpler and less expensive
echnologies such as ultrasounds. In most cases,
he new technologies are deployed into clinical
ractice before their incremental and additive
alue has been demonstrated through the conven-
ional process of health technology assessment
18,19). However, in a new environment of
ealthcare cost-containment, minimization of
isks related to imaging such as ionizing radia-
ions (20), stress echocardiography with dual
maging seems to be the appropriate tool to be
mplemented in the everyday clinical practice due
o its high negative predictive value, low cost,
ack of ionizing radiations, and wide availability.
n fact, in large series of unselected patients
eferred to high-volume stress echocardiography
aboratories, stress test results should influence
linical management. The benign prognostic im-
lications of a nonischemic stress echocardiogra-
hy with normal CFR on LAD should reduce the
eed for coronary angiography, representing the
ssential step for coronary revascularization only
n case of extensive test positivity or markedly
educed CFR. The presence of a severely reduced
FR with no inducible ischemia by wall motion
riteria may identify a group with relevant micro-
ascular impairment that is not prognostically
eutral as also shown in patients with hyperten-
ion (5), diabetes (3), and normal or near-normal
oronary arteries (4). Dual-imaging stress echo-
ardiography with dipyridamole has reached the
tatus of an established technique that needs to be
mplemented in clinical echocardiography labo-
atories with appropriate training and technology
pgrading. All these echocardiography parame-
ers are entwined to provide an accurate and
owerful risk stratification with the perfect tai-Study limitations. In this study, there was no central
eading. Stress echocardiography and CFR mea-
urement were interpreted in the peripheral centers,
nd data were entered directly into the databank.
his system allowed substantial sparing of human
nd technological resources, but it was also the
ogical prerequisite for a large-scale study, designed
o represent the realistic performance of the test
ather than the results of a single laboratory or even
single person working in a highly dedicated
chocardiography laboratory. Because the assess-
ent of the echocardiograms was qualitative and
ubjective, variability in reading the echocardio-
rams might have modulated the results of indi-
idual centers (21). However, all our readers in
ndividual centers had a long-lasting experience
n echocardiography, passed the quality control in
tress echocardiography reading as previously de-
cribed (15). The CFR was sampled only on
AD. There is no doubt that the 3 coronaries
pproach would be more fruitful, but at present it
emains too technically challenging for a large-
cale assessment. Forty-two percent of the patient
opulation underwent dipyridamole stress echo-
ardiography while receiving anti-ischemic med-
cal therapy, which may have offset myocardial
schemia. Nevertheless, therapy exerts a negligi-
le effect on the diagnostic (5) and prognostic (7)
value of CFR. In the current study, follow-up was
censored at the time of revascularization, and no
data are available on the effect of treatments
(surgery or angioplasty).
C O N C L U S I O N S
Mortality is the most relevant endpoint in risk
stratification, and stress echocardiography with the
combined approach of wall motion analysis and
CFR on LAD is able to independently predict
such a catastrophic event. Patients with a nega-
tive stress echocardiography and normal CFR are
at very low risk for death (1%/year). It is very
difficult to demonstrate that even the most ag-
gressive treatments might lower this rate of
death.
Reprint requests and correspondence: Dr. Rosa Sicari,
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